X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5%
Wed, 13 Feb

SUN PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

SUN PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m66,53269,37677,40211.6%16.3%
Other incomeRs m1,2923,5121,931-45.0%49.4%
TurnoverRs m67,82472,88879,3338.8%17.0%
ExpensesRs m51,99954,06455,8733.3%7.5%
Gross profitRs m14,5343,16821,529579.5%48.1%
DepreciationRs m3,3934,2654,71110.4%38.8%
InterestRs m9531,2951,44811.8%51.9%
Profit before taxRs m11,4791,11917,3011445.6%50.7%
TaxRs m7,4872,1892,70923.8%-63.8%
Profit after taxRs m3,992-1,07014,592265.5%
Gross profit margin%21.84.627.8
Effective tax rate%65.2195.615.7
Net profit margin%5.9-1.518.4
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 16.3% on a year-on-year (YoY) basis. The expenses were up by 7.5% YoY during the same period.
  • The company's operating profit increased by 48.1% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 27.8% in 3QFY19 as against 21.8% in 3QFY18.
  • Depreciation charges increased by 38.8% and finance costs increased by 51.9% YoY, respectively.
  • Other income increased by 49.4% YoY during the quarter.
  • Net profit for the quarter increased by 265.5% YoY. Net profit margins during the quarter increased from 5.9% in 3QFY18 to 18.4% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 11.6% on a quarter-on-quarter (QoQ) basis. The expenses were up by 3.3% QoQ during the same period.
  • The company's operating profit increased by 579.5% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 27.8% in 3QFY19 as against 4.6% in 2QFY18.
  • Net profit for the quarter increased by 1464.1% QoQ, while net profit margins increased from -1.5% in 2QFY18 to 18.4% in 3QFY19.

To see how SUN PHARMA has performed over the last eight quarters, please visit here.

SUN PHARMA Share Price Performance

Over the last one year, SUN PHARMA share price has moved up from Rs 589.4 to Rs 453.0, registering a Loss of Rs 136.4 or around 23.1%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,859.9 (up 0.7%). Over the last one year it has moved down from 14,517.2 to 13,859.9, a gain of 657 points (down 4.5%).

Overall, the S&P BSE SENSEX is up 5.8% over the year.

Current Valuations

At the current price of Rs 453.0, the price to earnings (P/E) ratio of SUN PHARMA stands at 27.2 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.9 times.

Equitymaster requests your view! Post a comment on "SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5%". Click here!

  

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - MYLAN COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS